Adverts

Open Access Articles- Top Results for Becampanel

Becampanel

</th></tr>
Becampanel
File:Becampanel.svg
Systematic (IUPAC) name
({[(2,3-Dihydroxy-7-nitro-5-quinoxalinyl)methyl]amino}methyl)phosphonic acid
Clinical data
Identifiers
188696-80-2
None
PubChem CID 5491960
ChemSpider 4590791
Chemical data
Formula C10H11N4O7P
330.191 g/mol

Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM).[1][2][3][4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.[1][2][3][5]

See also

References

  1. ^ a b John B. Taylor; D. J. Triggle (2007). Comprehensive medicinal chemistry II. Elsevier. p. 290. ISBN 978-0-08-044513-7. 
  2. ^ a b Kwan P, Brodie MJ (September 2007). "Emerging drugs for epilepsy". Expert Opin Emerg Drugs 12 (3): 407–22. PMID 17874969. doi:10.1517/14728214.12.3.407. 
  3. ^ a b Citraro R, Aiello R, Franco V, De Sarro G, Russo E (March 2014). "Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy". Expert Opin. Ther. Targets 18 (3): 319–34. PMID 24387310. doi:10.1517/14728222.2014.874416. 
  4. ^ World Health Organization (1988). International Nonproprietary Names (INN) for Pharmaceutical Substances. W.H.O. 
  5. ^ Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK (September 2010). "Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices". Drug Discov. Today 15 (17-18): 717–32. PMID 20603226. doi:10.1016/j.drudis.2010.06.014. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.